Zydus Cadila to introduce more drugs to the local market

Zydus Cadila, one of India's top four pharmaceutical companies with a group turnover of Indian Rs. 15000 Million and the second largest pharmaceutical company in Sri Lanka hopes to expand its local operations and increase the variety of drugs currently being supplied to the local market .

Zydus Cadila's Plants are approved by US FDA, MHRA UK, MCC South Africa and ANVISA Brazil to name a few of the worlds most strict pharmaceutical regulators. Executive Director Zydus Cadila, Ganesh Nayak, who visited Sri Lanka said that currently his organisation was present in all the key segments such as Cardiac, Gastro, Asthma and Anti infectives in Sri Lanka .

He added that Sri Lanka's asthma patients could also look forward to 3 more DPI's as well as 8 Metered Dose Inhalers [MDI's] from Zydus Cadila . The market for Anti Asthmatics is growing fast, estimated at 10%, while in Sri Lanka Asthmatics constitute around 6.7% of the market.

Nayak said that their range of MDI's would be more cost effective than the ones currently available in the market. Zydus Cadila hopes to launch a wide range of drugs to the local market later this year.